Ascher-Svanum Haya, Faries Douglas E, Zhu Baojin, Ernst Frank R, Swartz Marvin S, Swanson Jeff W
Eli Lilly and Co., Indianapolis, Ind, USA.
J Clin Psychiatry. 2006 Mar;67(3):453-60. doi: 10.4088/jcp.v67n0317.
Relatively little is known about the relationships between medication adherence and long-term functional outcomes in the treatment of schizophrenia. To extend previous research, we prospectively examined the relationships between adherence with any antipsychotic medication and functional outcomes among schizophrenia patients treated over a 3-year period, assessed the stability of adherence over time, and examined whether adherence in the first year predicts changes in functional outcomes over the following 2 years.
Analyses included 1906 participants with DSM-IV diagnoses of schizophrenia or schizoaffective or schizophreniform disorder in a multi-site, 3-year, prospective, naturalistic study conducted in the United States between July 1997 and September 2003. Outcome measures were assessed at 6-month intervals using systematic medical record abstraction and structured interview of patients. Adherence with antipsychotic regimen was assessed using patient-reported adherence and the medication possession ratio (percent days with prescription for any antipsychotic), dichotomized into adherence and non-adherence. Analyses employed generalized estimating equations and mixed models with repeated measures.
Nonadherence was associated with poorer functional outcomes, including greater risks of psychiatric hospitalizations, use of emergency psychiatric services, arrests, violence, victimizations, poorer mental functioning, poorer life satisfaction, greater substance use, and more alcohol-related problems (all p < .001). Adherence was relatively stable, with 77.3% of patients maintaining the same adherence status from the first year to the second year. Nonadherence in the first year predicted significantly poorer outcomes in the following 2 years.
Findings highlight the importance of adherence with antipsychotic medication in the long-term treatment of schizophrenia and its potential beneficial impact on the mental health and criminal justice delivery systems.
在精神分裂症治疗中,关于药物依从性与长期功能结局之间的关系,我们所知相对较少。为了拓展先前的研究,我们前瞻性地考察了在3年期间接受治疗的精神分裂症患者中,服用任何抗精神病药物的依从性与功能结局之间的关系,评估了依从性随时间的稳定性,并考察了第一年的依从性是否能预测接下来2年功能结局的变化。
分析纳入了1906名参与者,他们在美国1997年7月至2003年9月期间进行的一项多中心、为期3年的前瞻性自然主义研究中,被诊断为DSM-IV标准下的精神分裂症、分裂情感性障碍或精神分裂症样障碍。使用系统的病历摘要和对患者的结构化访谈,每隔6个月评估一次结局指标。使用患者报告的依从性和药物持有率(任何抗精神病药物有处方的天数百分比)评估抗精神病治疗方案的依从性,将其分为依从和不依从两类。分析采用广义估计方程和重复测量的混合模型。
不依从与较差的功能结局相关,包括更高的精神病住院风险、使用急诊精神科服务、被捕、暴力行为、受害、较差的心理功能、较差的生活满意度、更多的物质使用以及更多与酒精相关的问题(所有p < .001)。依从性相对稳定,77.3%的患者从第一年到第二年保持相同的依从状态。第一年的不依从预测接下来2年的结局明显更差。
研究结果凸显了抗精神病药物依从性在精神分裂症长期治疗中的重要性,以及其对心理健康和刑事司法系统的潜在有益影响。